Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Positions Uloric To Gout Patients In Need Of Better Control

Executive Summary

Takeda will focus its initial marketing effort for Uloric (febuxostat) - the first new treatment for gout in more than 40 years - on health care providers whose patients have highly elevated uric acid levels or continue to experience painful flares despite being on treatment
Advertisement

Related Content

Waiting For Next Regulatory Shoe To Drop For Takeda's Gout Drug Uloric
CV Trials For Symptomatic Conditions Feasible But Not Always Practical, FDA Panel Says
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Febuxostat Approval Still Leaves Many Questions For Lively Gout Market
Gout Pipeline Looks Past Uloric To Resistant Patients, Acute Flares
Savient Suggests More Restrictive REMS Plan For Pegloticase In BLA Amendment
PPI Market Snapshot: Kapidex Joins The Party Fashionably Late
FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?

Topics

Advertisement
UsernamePublicRestriction

Register

PS050734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel